3-吗啉羧酸 | 77873-76-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-吗啉羧酸
• 中文别名: 3-吗啉甲酸
• 英文名称: morpholine-3-carboxylic acid
• 英文别名: 3-Morpholinecarboxylic acid；morpholin-4-ium-3-carboxylate
• CAS: 77873-76-8
• 化学式: C₅H₉NO₃
• mdl: MFCD01318649
• 分子量: 131.131
• InChiKey: JUNOWSHJELIDQP-UHFFFAOYSA-N

物化性质

• 熔点：
  245-250℃
• 沸点：
  298.5±35.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Morpholinecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Morpholinecarboxylic acid
CAS number: 77873-76-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9NO3
Molecular weight: 131.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-吗啉羧酸 在 硫酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 20.0h， 生成 4-benzyl 3-methyl morpholine-3,4-dicarboxylate
  参考文献：
  名称：

  HEXAHYDROOXAZINOPTERINE COMPOUNDS

  摘要：

  本发明提供了一种mTOR抑制剂，其化学式如下，其中变量的定义如本文所述。还提供了包含这些化合物的药物组合物、试剂盒和制造物品；制备这些化合物和其中间体的方法；以及使用这些化合物的方法。

  公开号：

  US20110053921A1
• 作为产物：
  描述：

  4-乙酰基吗啉-3-甲腈 以55%的产率得到3-吗啉羧酸
  参考文献：
  名称：

  胡椒酸及其类似物的新合成

  摘要：

  胡椒酸同类物由α-氰基酰胺合成，该α-氰基酰胺是通过将α-甲氧基酰胺的酰胺基烷基化产物氧化的另一种途径，用三甲基甲硅烷基氰化物取代α-甲氧基酰胺而获得的。

  DOI：

  10.1016/0040-4039(81)80170-0

文献信息

• Synthesis and Aqueous Chemistry of α-Acetoxy-<i>N</i>-nitrosomorpholine:  Reactive Intermediates and Products
  作者：Charles N. Zink、Hyun-Joong Kim、James C. Fishbein

  DOI：10.1021/jo051936z

  日期：2006.1.1

  reactivity of 7 at neutral pH compared with its carbon analogue, α-acetoxy-N-nitrosopiperidine, is also consistent with the electronic effects expected for such a reaction. The dinitrophenylhydrazones derived from pH-independent and acid-catalyzed reactions are identical in kind and quantity, within experimental error, to those observed in the decay of α-hydroxy-N-nitrosomorpholine. Decay of 7 in the presence

  α-乙酰氧基-N-亚硝基吗啉（7）是通过N-乙酰基吗啉在甲醇中的阳极氧化反应开始合成的。经过氰化物为甲氧基的交换和水解后，N-亚硝基吗啉酸的55％收率比我们最初的10步法提高了约10倍，并且很容易转化为7。在1至12的pH范围内，在25°C和1 M离子强度下在水性介质中7的分解动力学进行了研究。在所有pH值下反应均表现出良好的一级动力学。k 0的对数，针对pH的与缓冲液无关的分解速率常数表明，pH无关的反应在中性pH区域占主导，而酸催化和碱催化的反应分别在低pH和高pH区域占主导。在醋酸盐离子浓度增加的情况下，在中性pH下反应会导致k obsd值降低至一个明显的极限值，该值与通过捕获N和竞争性碱催化水合N引起的普通离子抑制相一致。-亚硝基亚胺离子中间体。7在中性pH下的反应活性比其碳类似物α-乙酰氧基N小100倍-亚硝基哌啶也与这种反应预期的电子效应相一致。在实验误差范围内，与pH无关和酸
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Schering Corporation

  公开号：US20040106794A1

  公开（公告）日：2004-06-03

  There are disclosed compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。
• ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
  申请人：Board of Regents, The University of Texas System

  公开号：US20190270739A1

  公开（公告）日：2019-09-05

  The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.

  本发明涉及乙二胺-杂环化合物，能够作为PRMTs（蛋白精氨酸甲基转移酶）的抑制剂，用于治疗由PRMTs介导的癌症和其他疾病。
• [EN] MACROCYCLIC INDOLES AS MCL-1 INHIBITORS<br/>[FR] INDOLES MACROCYCLIQUES SERVANT D'INHIBITEURS DE MCL-1
  申请人：ASCENTAGE PHARMA SUZHOU CO LTD

  公开号：WO2020103864A1

  公开（公告）日：2020-05-28

  Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

  披露了公式I的化合物以及其中所述的药用可接受盐和溶剂化物，其中R，R1a，R1b，R1h，L1，L2，L3，Ⓐ，Ⓑ，Ⓒ如说明书中所定义。披露了公式I的化合物，用于治疗对Mcl-1抑制有反应的条件或疾病，如癌症。
• [EN] TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES ET COMPOSITIONS UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：NOVARTIS AG

  公开号：WO2017103824A1

  公开（公告）日：2017-06-22

  The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.

  本发明提供了如下式(A)的化合物：(I)以及所述化合物的盐，以及这些化合物用于治疗与Raf激酶活性相关的疾病的治疗用途。本发明进一步提供了包含这些化合物的药物组合物，以及包含这些化合物和治疗协同剂的组合物，以及使用这些组合物和组合物来治疗包括癌症在内的病症的方法。